Pharmaceutical

Cara Therapeutics cuts 50% of staff and drops kidney disease program

The company ceased activity for its CKD program to sharpen its clinical focus in the Phase II/III program for notalgia paresthetica.

Jan 23, 2024 - 18:00
Cara Therapeutics cuts 50% of staff and drops kidney disease program
The company ceased activity for its CKD program to sharpen its clinical focus in the Phase II/III program for notalgia paresthetica.
Read the original article

Tags:

Previous Article

STAT+: Feds bar Theranos founder Elizabeth Holmes from government health programs

Next Article

Newly launched Calluna raises $81m to advance monoclonal antibody pipeline

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo

Recordati to acquire worldwide rights to Sanofi’s antib...

Oct 6, 2024

STAT+: An injectable gel enters the male birth control fray with early positive clinical data

STAT+: An injectable gel enters the male birth control ...

Jan 4, 2024

Peptic Ulcers drugs in development, 2023

Nov 30, 2023